(Sharecast News) - AstraZeneca announced on Thursday that the European Commission (EC) has approved Bydureon BCise - exenatide 2mg prolonged-release suspension for injection in pre-filled pen - as a ...

Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. <10yrs: not established. Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Inject immediately after mixing. ≥10yrs: 2mg once ...

New formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight loss Across two clinical trials, average HbA1c reductions of up to 1.4% ...

On Wednesday, Vivani Medical, Inc. (NASDAQ:VANI) reported preclinical liver fat results with its exenatide implant for obese patients. Exenatide is sold by AstraZeneca Plc (NASDAQ:AZN) under the brand ...

As experts forecast GLP-1 medications boosting national economies, the manufacturers of these popular drugs have reported fruitful second quarters. AstraZeneca, the maker of Byetta, Bydureon and ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide (Byetta, ...